Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Delavirdine mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 87
States / cities: Birmingham, Alabama • Berkeley, California • Clovis, California + 63 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 13 more

Conditions: HIV Infections, Anus Neoplasms
Interventions: Isotretinoin, Interferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: Interferon alfa-n3; Drug
Lead sponsor: Interferon Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer
Interventions: Monopolar electrocautery loop in Transurethral resection of bladder tumors, PK Button Vaporization Electrode in transurethral resection of bladder tumors; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Female Stress Incontinence, Pelvic Organ Prolapse
Interventions: Elevate PC, Mini Arc Pro, RetroArc; Device
Lead sponsor: ASTORA Women's Health; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 6
States / cities: Alpharetta, Georgia • Morristown, New Jersey • Winston-Salem, North Carolina + 3 more

Conditions: HIV Infections
Interventions: Saquinavir, Nevirapine, Zidovudine, Zalcitabine; Drug
Lead sponsor: Parexel; Industry
Eligibility: 13 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: Nimodipine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 12
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 7 more

Conditions: HIV Infections
Interventions: Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bacterial Infections, Mycoses, HIV Infections
Interventions: Clarithromycin, Rifabutin, Sulfamethoxazole-Trimethoprim, Dapsone, Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 2
States / cities: San Francisco, California • Seattle, Washington

Conditions: Dermatitis, Photoallergic
Interventions: Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: HIV Infections
Interventions: F105 Monoclonal Antibody (Human); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Ditiocarb sodium; Drug
Lead sponsor: Merieux Institute; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 5 more

Conditions: Lymphatic Disease, HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: HIV Infections
Interventions: Curdlan sulfate; Drug
Lead sponsor: AJI Pharma USA; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: HIV Infections, Tuberculosis
Interventions: Tuberculin Purified Protein Derivative; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 14
States / cities: New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more

Conditions: HIV Infections
Interventions: Peptide T; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1988
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemorrhagic Stroke, Augmented Renal Clearance
Interventions: No intervention; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Dextran sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more

Conditions: HIV Infections, Cytopenias
Interventions: Interleukin-3; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions: Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1996
U.S. locations: 13
States / cities: Denver, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more

Conditions: HIV Infections, Measles
Interventions: Attenuvax, M-M-R-II; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 7 Months
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2001
U.S. locations: 43
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 29 more

Search by objective public record fields.

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors

Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1

A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV

A Study of DTC in Patients With AIDS and AIDS Related Complex

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy

Phase I/II Study of Curdlan Sulfate

A Study of Isoprinosine in Patients With Severe AIDS

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

ARC in Hemorrhagic Stroke

A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)

A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

A Study of Psychosocial and Behavioral Determinants of Differential Rates of Participant Compliance in CPCRA Protocols

A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group